entertainment -WSS

entertainment

author：hotspot 2025-08-26 07:45:14 - browse：217

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Late stage cancers on the rise after pandemic delayed screenings

focus

WSS

FDA scientists endorse Pfizer/BioNTech Covid

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Medicare slashes safety net hospital payments by nearly $1 billion

Review: 'Barbie' will hit you like a shot in the heart

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

AbbVie dramatically boosts its spending on lobbying

focus

entertainment

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

How to save PrEP access — and even expand it

A double vaccine crisis is endangering millions of children

Heart attack and stroke risk calculators need revising

How to ethically and practically extend health care to all

How one medical school became remarkably diverse

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Anesthesiologist group: stop taking Ozempic before surgery

Caitlin Bernard's story shows physicians can't shy from advocacy

hotspot

In new study, freeze

H.R. 3 is the wrong path to lower drug costs

Court strikes down limits on filming of police in Arizona

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Group behind ProMed defends move to subscription

focus

focus

explore

leisure time